



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Gębicki *et al.*

App. No.: 10/585,892

35 U.S.C. § 371 Date: July 11, 2006

U.S. Nat'l Stage of PCT/EP05/50057;

I.A. Fd: January 7, 2005

For: **Use of Quaternary Pyridinium  
Salts as Vasoprotective Agents**

Confirmation No.: 7625

Art Unit: 1614

Examiner: Nelson Clarence Blakely III

Atty. Docket: 2782.0010001/MAC

**Fourth Supplemental Information Disclosure Statement**

**under 37 C.F.R. § 1.97(c)**

***Mail Stop Amendment***

Commissioner for Patents  
PO Box 1450  
Alexandria, VA 22313-1450

Madam Commissioner:

Listed on accompanying IDS Forms PTO/SB/08A and PTO/SB/08B are documents that may be considered material to the patentability of this application as defined in 37 C.F.R. §1.56, and/or compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.97 and 1.98.

Document numbering on this fourth supplemental information disclosure statement (IDS) is a continuation of the numbering of the third supplemental IDS filed February 27, 2009.

A copy of each of documents NPL1 and NPL2 is provided. A copy of document US5, a published US patent application, is not provided.

Where the publication date of a listed document does not provide a month of publication, the year of publication of the listed document is sufficiently earlier than the

05/22/2009 MAHMED1 00000102 10585892  
01 FC:1806

180.00 OP

effective U.S. filing date and any foreign priority date so that the month of publication is not in issue.

Applicants have listed publication dates on the attached IDS Forms based on information presently available to the undersigned. However, the listed publication dates should not be construed as an admission that the information was actually published on the date indicated.

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist. The Examiner is specifically requested not to rely solely on the material submitted herewith.

This Information Disclosure Statement is being filed after the mailing date of a first Office Action on the merits but before the mailing of a final Office action. It is accompanied by the appropriate fee. 37 C.F.R. § 1.17(p).

It is respectfully requested that the Examiner initial and return a copy of the enclosed IDS Forms, and indicate in the official file wrapper of this patent application that the documents have been considered. The U.S. Patent and Trademark Office is

hereby authorized to charge any fee deficiency, or credit any overpayment, to our  
Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



Michele A. Cimbala  
Attorney for Applicants  
Registration No. 33,851

Date: May 21, 2009

1100 New York Avenue, N.W.  
Washington, D.C. 20005-3934  
(202) 371-2600

971098\_1.DOC